Premium
The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia: Proposals by the French ‐ American ‐ British Cooperative Leukaemia Group
Author(s) -
Bennett J. M.,
Catovsky D.,
Daniel M. T.,
Flandrin G.,
Galton D. A. G.,
Gralnick H.,
Sultan C.,
Cox C.
Publication year - 1994
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1994.tb06734.x
Subject(s) - chronic myeloid leukaemia , chronic myelomonocytic leukemia , breakpoint cluster region , medicine , myeloid , dysplasia , bone marrow , immunology , cancer research , oncology , myelodysplastic syndromes , receptor
Summary. We have reviewed our experience with four of the entities that are included under the generic term chronic myeloid leukaemia (CML), namely the classic Ph + CGL, both BCR + and BCR − , aCML and CMML. We have developed a statstical model that confirms that CGL, aCML and CMML can be distinguished from each other with reasonable success employing five quantitative parameters (WBC, percentage immature granulocytes, percentage monocytes, percentage basophils, percentage erythroid precursors in bone marrow) and one qualitative parameter (granulocytic dysplasia). It is hoped that these detailed recommendations will enable investigators to improve their diagnostic accuracy. This should permit more uniform comparisons of molecular biologic and clinical studies.